Current research projects
Clinical Trials
Glomerulopathies
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (I CAN)
- A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis (MISSION)
- A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)
- Phase 3, multicentre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of sibeprenlimab administered subcutaneously in subjects with immunoglobulin A nephropathy
- Metformin versus Tolvaptan in adults with Autosomal Dominant Plycystic Kidney Disease: a phase 3a, indipendent, multi-centre, 2 parallel arms randomized-controlled trial
- Sperimentazione di fase 3, multicentrica, randomizzata, in doppio cieco, controllata con placebo per valutare l’efficacia e la sicurezza di sibeprenlimab somministrato per via sottocutanea in soggetti con nefropatia da immunoglobulina A
- 18-month, open-label, single-arm safety extension study of an age and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults (1 to 18 years) with chronic kidney disease and proteinuria
- A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
- A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomeruloscle
- Phase 3, randomized, double-blind, active versus control cycle to evaluate the safety and efficacy of CCX168 (Avacopan) in patients with cytoplasmic antineutrophil associated vasculitis (ANCA) in combination with rituximab ofosfamide / azathioprine.
- A Phase 3, Randomized, Double-blinded, Placebo-controlled, multicenter study to evaluate the efficacy and safety of Pegcetacoplan in patients with primary C3 glomerulopathy or Immuno-Complex Membranoproliferative Glomerulonephritis
- A PHASE III, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS EUDRACT
- 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age- & body weight-adjusted oral finerenone regimen, in addition to an ACEI/ARB, for the treatment of child. with chronic kidney dis.
- The FIONA Study
- Obinutuzumab in Primary MN (ORION)
- A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (lgAN)
- MONET STUDY
- A 9-year, Multicentre, Non-interventional, Post-authorisation Safety Study for Patients Prescribed JINARC® for Autosomal Dominant Polycystic Kidney Disease
- A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy
- Phase 3 study to evaluate the efficacy and safety of LNP023 on proteinuria and renal function decline in primary IgA nephropathy patients
- Phase 3 study to evaluate the efficacy and safety of LNP023 on proteinuria and renal function decline in primary IgA nephropathy patients
- A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY
- Phase 2, double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN)
- A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy (MAJESTY)
- A Phase 3, Randomized, Double-blind, Placebocontrolled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)
- Phase 3, randomized, blinded, multicentre, placebo-controlled study to evaluate the efficacy and safety of Inebilizumab in IgG4-related disease (MITIGATE).
- Multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Obinutuzumab in patients with class III or IV lupus nephritis according to ISN / RPS 2003 criteria
- A randomized, multicenter, double-blind, parallel, active-control study of the effects of Sparsentan, a dual endothelin receptor and angiotensin receptor blocker, on renal outcomes in patients with primary focal segmental glomerulosclerosis
- Treatment of IGA nEphropathy according to Renal lesions (TIGER)
- A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY- 021IGAN17001
- OL Extension Study of LNP023 in C3G
- A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVECONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
- AN EXTENDED ACCESS PROGRAM TO ASSESS LONG TERM SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE (EAGLE)
- LEARNS: Levamisole as Adjuvant therapy to Reduce relapses of Nephrotic Syndrome
- PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN(RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITHFOCALSEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY
- Genetic, genomic, and biomarker studies of Henoch-Schönlein purpura and IgA nephropathy in kids
Tubulopathies and metabolic disorders
- QUALIFY- Development of a patient-reported outcome to measure the health-related quality of life of children and adolescents with cystinosis
- GENESIS - Genetic Newborn Screening for Cystinosis and Hyperoxaluria
- OCULAR BIOMARKERS - Validation of ocular OCT-based biomarkers for corneal and systemic disease activity in infantile nephropathic cystinosis
- A PHASE 2 OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DCR-PHXC IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 OR 2 AND SEVERE RENAL IMPAIRMENT, WITH OR WITHOUT DIALYSIS “PHYOX7” (DCR-PHXC-204)
- ILLUMINATE-C
- Roll over study to evaluate the safety and long term efficacy of DCR-PHXC in patient with Primary Hyperoxaluria (DCR-PHXC-301)
Thrombotic microangiopathies
- Multicentre study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of crovalimab in pediatric patients with atypical HUS
- Tailorig Complement inhibition for Thrombotic microangiopathies
- Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS)
Structural Kidney Disorders
- 18-month, open-label, single-arm safety extension study of an age and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults (1 to 18 years) with chronic kidney disease and proteinuria
- 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age- & body weight-adjusted oral finerenone regimen, in addition to an ACEI/ARB, for the treatment of child. with chronic kidney dis.
- The FIONA Study
CKD and Dialysis in Children
- A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
- Development, validation and clinical reliability of a predictive machine learning model for volume management in pediatric intensive care unit
- 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age- & body weight-adjusted oral finerenone regimen, in addition to an ACEI/ARB, for the treatment of child. with chronic kidney dis.
- The FIONA Study
- A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
Pediatric Kidney Transplantation
- 18-month, open-label, single-arm safety extension study of an age and bodyweightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults (1 to 18 years) with chronic kidney disease and proteinuria
- A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK’s PED-HZ/su in paediatric renal transplant recipients (GSK , UK)
- A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
Cohort Studies and Registries
Glomerulopathies
- Subregistry on ANCA Associated Vasculitis
- The CompCure Project and Registry
- Fabry Disease Registry Protocol
- Pediatric SLE Registry
- PREGeNEPH Registry - Pregnany, Genetics & Nephrology
- Analisi di pazienti affetti da Malattia di Anderson-Fabry
- Magnetic resonance Imaging of Cysts KidneY Volume and microstructure in ADPKD patients: a retrospective study
- Analisi di pazienti affetti da Rene Policistico Autosomico Dominante
- Registro per la ricerca scientifica e clinica sulla Sclerosi Tuberosa
- Global Kidney Patient Trials Network (GKPTN2019)
- Anonymous candidate gene identification
- Registro italiano ADPKD
- Evaluation of immune competence in children with idiopathic nephrotic syndrome
- GeNepher registry and biobank
- Recurrence of nephrotic syndrome after pediatric kidney transplantation” (SRNS2019) Certain project.
Tubulopathies and metabolic disorders
- ODAP (Orphan Drug Access protocol lumasiran)
- Stable isotopes in calcium-oxalate stone formers
- Bartter/Gitelman Registry
- Renal involvement in Coffin Siris syndrome
- SENTENCE - Structured multidisciplinary data collection for cystinosis
- PREGeNEPH Registry - Pregnany, Genetics & Nephrology
- EUROCYS Registry
- Anonymous candidate gene identification
- Natural history of patients with dRTA
- GeNepher registry and biobank
- International XLH Registry
- Chitotriosidase as a novel biomarker of cystinosis
Thrombotic microangiopathies
- MCPggaac as a risc factor for aHUS
- PREGeNEPH Registry - Pregnany, Genetics & Nephrology
- Anonymous candidate gene identification
- GeNepher registry and biobank
- aHUS REGISTRY
Structural Kidney Disorders
- ADTKD-Net
- AUTOSOMAL DOMINANT TUBULOINTERSTITIAL KIDNEY DISEASE-Net A European registry based clinical research platform
- ERKNet Survey on clinical manifestations and renal outcome in HNF1beta
- Late onset PKAR (> 18 years old): phenotype, gentoype and evolution
- Renal damage and evolution of kidney function in patients with Kabuki syndrome
- PREGeNEPH Registry - Pregnany, Genetics & Nephrology
- ArtDeco
- Italian Registry of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Anonymous candidate gene identification
- GeNepher registry and biobank
- ADPedKD: an international web-based database for longitudinal data registry of children with autosomal dominant polycystic kidney disease (ADPKD).
- AD(H)PKD - Evaluating ADPKD in the era of tolvaptan
CKD and Dialysis in Children
- The CompCure Project and Registry
- Long-term follow-up of children with chronic kidney disease
- Anonymous candidate gene identification
- European Registry for Children on Renal Replacement Therapy - ESPN-ERA Registry
- GeNepher registry and biobank
- International Peritoneal Biobank
- International Pediatric Dialysis Network (IPDN)
Pediatric Kidney Transplantation
- Long-term follow-up of children with chronic kidney disease
- COVID-19 AND FRAGILE PATIENTS: Multicenter observational study to assess the incidence and features of COVID-19 and the response to COVID-19 vaccination in fragile patients
- European Registry for Children on Renal Replacement Therapy - ESPN-ERA Registry
- Recurrence of nephrotic syndrome after pediatric kidney transplantation” (SRNS2019) Certain project.
- CERTAIN Registry
- International Peritoneal Biobank
Translational Research Projects
Glomerulopathies
- NEPHrotic syndrome from childhood to adulthood: creating a NETwork for research and care. The NEPHNET project
- Searching unsuspected inherited kidney diseases: a needle in a haystack (NLP)
- National Center for Gene Therapy and Drugs based on RNA Technology
- Systems Multiomics Approach for Precision Diagnostics of Idiopathic Nephrotic Syndrome
- USE OF ARTIFICIAL INTELLIGENCE AND SYSTEMS BIOLOGY FOR DIAGNOSIS AND PERSONALIZED RISK ASSESSMENT FOR INHERITED KIDNEY DISEASES, FOCUSING ON ALPORT SYNDROME
- International consortium for integrative genomics prediction (INTERVENE)
- NETs and terminal complement pathway as potential biomarkers for complement overactivation assessment in ANCA-associated vasculitis
- Phenotypic and functional characterization of lymphocytes, monocytes, and macrophages by flow cytometry of urinary sediment in patients with lupus nephritis for the prediction of chronic kidney disease
- Elucidating the genetic pathomechanism underlying rare and hereditary kidney diseases (RKD)
- Urinary Biomarkers: Analysis of Urine in patients with tubular and glomerular kidney disease
- Renal Biopsy Project
Tubulopathies and metabolic disorders
- Effect of diet in animal models of nephropathic cystinosis (Evaluation)
- Ketogenic diet for nephropathic cystinosis
- RNA therapy in cystinosis
- Searching unsuspected inherited kidney diseases: a needle in a haystack (NLP)
- Effect of diet on murine models of nephropathic cystinosis
- USE OF ARTIFICIAL INTELLIGENCE AND SYSTEMS BIOLOGY FOR DIAGNOSIS AND PERSONALIZED RISK ASSESSMENT FOR INHERITED KIDNEY DISEASES, FOCUSING ON ALPORT SYNDROME
- ACTIVITIES OF FLAVONOID LUTEOLIN IN A MOUSE MODEL OF NEPHROPATHIC CYSTINOSIS
- Pharmacoprotection in Cystic Nephropathies
- Elucidating the genetic pathomechanism underlying rare and hereditary kidney diseases (RKD)
- Urinary Biomarkers: Analysis of Urine in patients with tubular and glomerular kidney disease
Thrombotic microangiopathies
- Searching unsuspected inherited kidney diseases: a needle in a haystack (NLP)
- USE OF ARTIFICIAL INTELLIGENCE AND SYSTEMS BIOLOGY FOR DIAGNOSIS AND PERSONALIZED RISK ASSESSMENT FOR INHERITED KIDNEY DISEASES, FOCUSING ON ALPORT SYNDROME
- Elucidating the genetic pathomechanism underlying rare and hereditary kidney diseases (RKD)
- Urinary Biomarkers: Analysis of Urine in patients with tubular and glomerular kidney disease
Structural Kidney Disorders
- Theracil EU consortium
- Searching unsuspected inherited kidney diseases: a needle in a haystack (NLP)
- Aetiology of renal and urinary tract anomalies defines Diagnostic Efficacy and Clinical Outcome
- USE OF ARTIFICIAL INTELLIGENCE AND SYSTEMS BIOLOGY FOR DIAGNOSIS AND PERSONALIZED RISK ASSESSMENT FOR INHERITED KIDNEY DISEASES, FOCUSING ON ALPORT SYNDROME
- Pharmacoprotection in Cystic Nephropathies
- Elucidating the genetic pathomechanism underlying rare and hereditary kidney diseases (RKD)
- Urinary Biomarkers: Analysis of Urine in patients with tubular and glomerular kidney disease
CKD and Dialysis in Children
- Theracil EU consortium
- Pharmacoprotection in Cystic Nephropathies
- NPHP1-consortium
- Elucidating the genetic pathomechanism underlying rare and hereditary kidney diseases (RKD)
- Urinary Biomarkers: Analysis of Urine in patients with tubular and glomerular kidney disease